Musculoskeletal Health in Adult Haematological Cancer Survivors
- Conditions
- Cancer SurvivorsLymphomaLeukemiaMusculoskeletal Complication
- Interventions
- Other: Not an intervention study
- Registration Number
- NCT05865678
- Lead Sponsor
- The Christie NHS Foundation Trust
- Brief Summary
Haematological cancer treatment often includes use of high dose glucocorticoids (steroids), chemotherapy and radiotherapy and current evidence suggests that these patients may have lower bone mineral density after treatment when compared to the general population which can predispose them to increased risk of fragility fractures. Evidence of the impact of these musculoskeletal burden to patients (e.g. quality of life) are not available.
This study aims to describe musculoskeletal complications experienced by long-term haematological cancer survivors and examine the impact of the burden from the patient perspective. The study will be conducted in 2 parts; a questionnaire study and an interview study to help understand the extent of musculoskeletal problems experienced by this group of patients and the impact of this on quality of life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 650
- Age 18 or above at diagnosis of haematological cancer
- Diagnosis of haematological cancers: lymphoma or leukaemia
- Cancer survivors as recorded in the local database of lymphoma and haematopoietic stem cell transplant database
- Able to give written informed consent
- Able to read and understand English
1.Currently receiving any active cancer treatment
Interview study
Inclusion Criteria:
- Age 18 or above at diagnosis of haematological cancer
- Diagnosis of haematological cancers: lymphoma or leukaemia
- Cancer survivors as recorded in the local database of lymphoma and haematopoietic stem cell transplant database
- Able to give written or verbal informed consent
- Able to read and understand English
Exclusion Criteria:
1 .Currently receiving any active cancer treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 5-10 years post cancer treatment; female; age at diagnosis 18-30 Not an intervention study - 11-20 years post cancer treatment; male; age at diagnosis 31-50 Not an intervention study - 5-10 years post cancer treatment; female; age at diagnosis 51-70 Not an intervention study - 21-30 years post cancer treatment; female; age at diagnosis 70+ Not an intervention study - 11-20 years post cancer treatment; male; age at diagnosis 51-70 Not an intervention study - 5-10 years post cancer treatment; male; age at diagnosis 18-30 Not an intervention study - 5-10 years post cancer treatment; male; age at diagnosis 31-50 Not an intervention study - 5-10 years post cancer treatment; male; age at diagnosis 51-70 Not an intervention study - 5-10 years post cancer treatment; male; age at diagnosis 70+ Not an intervention study - 11-20 years post cancer treatment; male; age at diagnosis 18-30 Not an intervention study - 11-20 years post cancer treatment; female; age at diagnosis 18-30 Not an intervention study - 11-20 years post cancer treatment; female; age at diagnosis 51-70 Not an intervention study - 11-20 years post cancer treatment; female; age at diagnosis 70+ Not an intervention study - 21-30 years post cancer treatment; male; age at diagnosis 51-70 Not an intervention study - 5-10 years post cancer treatment; female; age at diagnosis 31-50 Not an intervention study - 5-10 years post cancer treatment; female; age at diagnosis 70+ Not an intervention study - 11-20 years post cancer treatment; male; age at diagnosis 70+ Not an intervention study - 21-30 years post cancer treatment; male; age at diagnosis 18-30 Not an intervention study - 21-30 years post cancer treatment; female; age at diagnosis 18-30 Not an intervention study - 30 years + post cancer treatment; female; age at diagnosis 70+ Not an intervention study - 21-30 years post cancer treatment; male; age at diagnosis 70+ Not an intervention study - 11-20 years post cancer treatment; female; age at diagnosis 31-50 Not an intervention study - 30 years + post cancer treatment; male; age at diagnosis 31-50 Not an intervention study - 30 years + post cancer treatment; male; age at diagnosis 70+ Not an intervention study - 30 years + post cancer treatment; female; age at diagnosis 31-50 Not an intervention study - 21-30 years post cancer treatment; male; age at diagnosis 31-50 Not an intervention study - 21-30 years post cancer treatment; female; age at diagnosis 31-50 Not an intervention study - 21-30 years post cancer treatment; female; age at diagnosis 51-70 Not an intervention study - 30 years + post cancer treatment; male; age at diagnosis 18-30 Not an intervention study - 30 years + post cancer treatment; male; age at diagnosis 51-70 Not an intervention study - 30 years + post cancer treatment; female; age at diagnosis 18-30 Not an intervention study - 30 years + post cancer treatment; female; age at diagnosis 51-70 Not an intervention study -
- Primary Outcome Measures
Name Time Method Interivew study: To describe experience of adult lymphoma and leukaemia survivors on musculoskeletal health, musculoskeletal related care and musculoskeletal health information provision. overall length of the study - 6 months Semi-structured qualitative interviews will be conducted with a topic guide to ensure same broad topics are explored in the interviews on musculoskeletal health experience, care and information provision.
Questionniare study: To measure prevalence of sarcopenia and frailty among adult lymphoma and leukaemia survivors overall length of the study - 6 months Validated questionniares will be used to assess if patients have sarcopenia (SARC-F questionnaire) and frailty (FiND questionnaire).
Questionniare study: To calculate the 10-year probability of hip fracture and major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) of adult lymphoma and leukaemia survivors overall length of the study - 6 months The 10-year probability of hip fracture and major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) of adult lymphoma and leukaemia survivors will be calculated using the Fracture Risk Assessment Tool (FRAX) and Q-Fracture calculator.
Questionniare study: To measure prevalence of musculoskeletal conditions and related symptoms experienced by adult lymphoma and leukaemia survivors overall length of the study - 6 months Musculoskeletal conditions and related symptoms will be recorded by patients on the study specific questionnaire and the validated questionnaire Nordic musculoskeletal questionnaire (NMQ-E) and gait, arms, legs and spine (GALS) assessment
Questionniare study: To assess quality of life and musculoskeletal function related quality of life of adult lymphoma and leukaemia survivors overall length of the study - 6 months This will be assessed using validated questionnaires - Short Form Survey (SF36) and Short Musculoskeletal Function Assessment (SMFA).
- Secondary Outcome Measures
Name Time Method Questionnaire study: To describe the likely risk factors that may be associated with musculoskeletal consequences of adult lymphoma and leukaemia survivors Impact of musculoskeletal health overall length of the study - 6 months This will be assessed using regression analysis to determine risk factors that may be associated with poor musculoskeletal health
Trial Locations
- Locations (1)
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom